Women left unprotected amid illegal distribution
"No separate bridging study involving Koreans"

The government emphasized the need for a legal framework to ensure the safe use of Mifegyne, widely known as an abortion pill, and provide relief to those harmed by its side effects.


Oh Yu-kyung, minister of food and drug safety, answers lawmakers' questions during a parliamentary audit of the Ministry of Food and Drug Safety and other agencies at the National Assembly on Oct. 13, 2026. Photo by Yoon Dongju.

Oh Yu-kyung, minister of food and drug safety, answers lawmakers' questions during a parliamentary audit of the Ministry of Food and Drug Safety and other agencies at the National Assembly on Oct. 13, 2026. Photo by Yoon Dongju.

View original image

When Lee Man-hee, a lawmaker from the People Power Party, raised concerns about Mifegyne's side effects during a parliamentary audit by the National Assembly Health and Welfare Committee on Oct. 13, Minister of Food and Drug Safety Oh Yukyung said, "Young women in Korea are currently in a blind spot, using drugs illegally despite the serious concerns about side effects and receiving no protection," adding, "Given the safety concerns, it is right to provide women with a more legal way to seek redress for harm."


Minister Oh added, "As the problem of illegal use of abortion medications continues, I believe we need to find a way to bring this area further into the open."


Last month, the government announced its plan to introduce abortion medications, and the Ministry of Food and Drug Safety is pursuing the necessary procedures with the goal of introducing them by the first quarter of 2027.


Responding to calls for an apology to women over delays in approving abortion medications, Minister Oh said, "I am sorry." Asked when the product approval process would be completed, she replied, "The company is currently preparing supplementary materials for the product approval. We will conduct a thorough review as soon as the materials are submitted."


She reiterated that there are no plans for a bridging study of Mifegyne involving Korean participants. A bridging study examines whether a drug's safety and efficacy differ by ethnicity or country.



Minister Oh said, "As far as I know, no particular adverse reactions have been identified with Mifegyne by ethnicity or country."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing